Teva Pharmaceutical Industries Ltd (TEVA)

36.53
NYSE : Health Care
Prev Close 36.57
Day Low/High 36.41 / 37.11
52 Wk Low/High 36.41 / 66.55
Avg Volume 9.04M
Exchange NYSE
Shares Outstanding 1.01B
Market Cap 37.12B
EPS 1.80
P/E Ratio 7.26
Div & Yield 1.36 (3.70%)

Latest News

Teva To Present Oncology Data At The 2016 American Society Of Hematology (ASH) Annual Meeting & Exposition

Teva To Present Oncology Data At The 2016 American Society Of Hematology (ASH) Annual Meeting & Exposition

Teva Pharmaceutical Industries Ltd., (NYSE and TASE:TEVA) today announced that data on GRANIX ® (tbo-filgrastim) Injection, TREANDA ® (bendamustine HCl) Injection and TRISENOX ® (arsenic trioxide) Injection...

Some 'January Effect' Stock Picks

Some 'January Effect' Stock Picks

Small-caps could also benefit from abating tax-loss selling.

Allergan Could Pay $1 Billion for Chase Pharma

Allergan Could Pay $1 Billion for Chase Pharma

'Milestone payments' could boost deal's $125 million announced price.

Teva Pharmaceutical Industries Limited Investors With Losses In Excess Of $1,000,000 Are Reminded To Contact The Rosen Law Firm Regarding The Important Deadline In Class Action Filed By Firm - TEVA

Teva Pharmaceutical Industries Limited Investors With Losses In Excess Of $1,000,000 Are Reminded To Contact The Rosen Law Firm Regarding The Important Deadline In Class Action Filed By Firm - TEVA

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the American Depositary Shares ("ADSs") of Teva Pharmaceutical Industries Limited (NYSE:TEVA) between February 10, 2015 and November 3, 2016, both...

Teva Secures European Approval Of Trisenox® For First Line Treatment Of Low To Intermediate Risk Acute Promyelocytic Leukemia (APL)

Teva Secures European Approval Of Trisenox® For First Line Treatment Of Low To Intermediate Risk Acute Promyelocytic Leukemia (APL)

Teva Pharmaceutical Industries Ltd., (NYSE and TASE:TEVA) today announced it has obtained approval from the European Commission for an indication extension of Trisenox ® (arsenic trioxide).

INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Teva Pharmaceutical Industries Limited To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Teva Pharmaceutical Industries Limited To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Central District of California on behalf...

Nokia, Teva Pharmaceutical and Vodafone Are Volatile; Here's Why

Nokia, Teva Pharmaceutical and Vodafone Are Volatile; Here's Why

As the broader markets surge, these three stocks are falling. Are any of them value plays?

Analysts' Actions -- Disney, Fitbit, Fossil, Lululemon, Sysco and More

Analysts' Actions -- Disney, Fitbit, Fossil, Lululemon, Sysco and More

Here are Wednesday's top research calls, including upgrades for Disney, Fitbit and Fossil, and downgrades for Lululemon Athletica and Sysco.

Robbins Arroyo LLP: Teva Pharmaceutical Industries Ltd. (TEVA) Misled Shareholders According To A Recently Filed Class Action

Robbins Arroyo LLP: Teva Pharmaceutical Industries Ltd. (TEVA) Misled Shareholders According To A Recently Filed Class Action

Shareholder rights law firm Robbins Arroyo LLP announces that a class action complaint was filed against Teva Pharmaceutical Industries Ltd.

Cramer: This Is No Time to Dog-Paddle

Cramer: This Is No Time to Dog-Paddle

In these market crosscurrents, it's tough to go with the flow.

Teva Shares Lower on Third-Quarter Results

Teva Shares Lower on Third-Quarter Results

Teva's revenue was helped by its acquisition of Allergan's generics business in the third quarter, though sales nonetheless missed estimates.

Teva Reports Third Quarter 2016 Results

Teva Reports Third Quarter 2016 Results

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) today reported results for the quarter ended September 30, 2016.

Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Teva Pharmaceutical Industries Limited - TEVA

Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Teva Pharmaceutical Industries Limited - TEVA

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the American Depositary Shares ("ADSs") of Teva Pharmaceutical Industries Limited (NYSE:TEVA)...

Pfizer Finds Breaking Up Is Hard to Do

Pfizer Finds Breaking Up Is Hard to Do

Pfizer stock took a dive. Now what?

War and Peace in Trumpland: Here Is Why You Buy These 4 Stocks Now

War and Peace in Trumpland: Here Is Why You Buy These 4 Stocks Now

After the shocking election results, the stock market supplied its own surprise and rallied Wednesday. These four gainers should continue thriving under a Donald Trump presidency.

INVESTOR ALERT: Law Offices Of Howard G. Smith Commences Investigation On Behalf Of Teva Pharmaceuticals Investors Concerning Recent Revelations Regarding An Alleged Illegal Conspiracy To Fix Drug Prices

INVESTOR ALERT: Law Offices Of Howard G. Smith Commences Investigation On Behalf Of Teva Pharmaceuticals Investors Concerning Recent Revelations Regarding An Alleged Illegal Conspiracy To Fix Drug Prices

Law Offices of Howard G. Smith announces an investigation on behalf of investors of Teva Pharmaceuticals ("Teva" or the "Company") (NYSE: TEVA) concerning recent reports that the Company has unlawfully colluded with...

IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Teva Pharmaceutical Industries Limited And Encourages Investors With Losses To Contact The Firm

IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Teva Pharmaceutical Industries Limited And Encourages Investors With Losses To Contact The Firm

Lundin Law PC, a shareholder rights firm, announces a class action lawsuit has been filed against Teva Pharmaceutical Industries Limited ("Teva" or the "Company") (NYSE: TEVA) concerning possible violations of federal...

Teva Announces Appointment Of New Chief Legal Officer

Teva Announces Appointment Of New Chief Legal Officer

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)(TASE:TEVA) today announced the appointment of Mr.

IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit Against Teva Pharmaceutical Industries Limited And Encourages Investors With Losses To Contact The Firm

IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit Against Teva Pharmaceutical Industries Limited And Encourages Investors With Losses To Contact The Firm

Khang & Khang LLP (the "Firm") announces the filing of a class action lawsuit against Teva Pharmaceutical Industries Limited ("Teva" or the "Company") (NYSE: TEVA).

Impax is Slowly Stealing Market Share from Mylan, but Manufacturing Could Get in the Way

Impax is Slowly Stealing Market Share from Mylan, but Manufacturing Could Get in the Way

Impax makes a generic version of Adrenaclick, a competitor to Mylan's EpiPen.

Teva Announces Approval Of Generic Tribenzor® In The United States

Teva Announces Approval Of Generic Tribenzor® In The United States

Teva Pharmaceutical Industries Ltd., (NYSE and TASE:TEVA) today announced approval of generic Tribenzor ®1(olmesartan medoxomil, amlodipine and hydrochlorothiazide) tablets in the U.

Teva Highlights Growing Respiratory Portfolio At The 2016 American College Of Allergy, Asthma & Immunology Annual Scientific Meeting

Teva Highlights Growing Respiratory Portfolio At The 2016 American College Of Allergy, Asthma & Immunology Annual Scientific Meeting

Teva Pharmaceutical Industries Ltd., (NYSE and TASE:TEVA) today announced that ten company-sponsored abstracts will be presented at the 2016 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific...

Cisco, Allergan, Facebook: Doug Kass' Views

Cisco, Allergan, Facebook: Doug Kass' Views

Doug Kass shares his thoughts on the bond market's bounciness and stocks suffering election uncertainty.

Opko Healthcare's Phillip Frost Is a Major Microcap Investor

Opko Healthcare's Phillip Frost Is a Major Microcap Investor

Opko Healthcare's CEO is chairman of an investment bank and number 134 on the Forbes 400 richest people in the world.

After Big Drop in Generics, Ride the Rebound

After Big Drop in Generics, Ride the Rebound

Investors have a buying opportunity because the damage by any criminal charges is far less than what is likely to be inflicted by the feds.